MedTrace Logo

Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF)

NCT06008704 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-05-11

No results posted yet for this study

Summary

This project will explore the involvement of the serotonin system in the pathophysiology of PD-related central pain. Thus, the serotonin system will be evaluated in PD patients with and without central pain who will benefit from brain positron emission tomography (PET) allowing in vivo imaging of 5HT1A receptors and multimodal brain MRI including morphometric imaging and functional connectivity (resting state acquisition).

Conditions

  • Parkinson Disease

Interventions

DIAGNOSTIC_TEST

Clinical assessment

The clinical assessment consists on behavioural and motor evaluations to determine the characteristics of the population

DIAGNOSTIC_TEST

Pain characteristics assessment

The pain characteristics assessment will be made with a variety of scales and questionnaires which allow to identify the extent of central pain and functional impairment

DIAGNOSTIC_TEST

MRI

The MRI examination allows anatomical imaging, diffusion imaging and functional imaging to measure specific markers

DIAGNOSTIC_TEST

Thermotest

The thermotest is performed to assess the pain perception threshold

DIAGNOSTIC_TEST

UPDRS-III Scale

The UPDRS-III scale allows to asses motor functionality of PD patients

DIAGNOSTIC_TEST

[18F]-MPPF PET scan

The PET scan after injection of \[18F\]-MPPF at a dose of 200 Megabecquerel/kg +/-10% allows in vivo imaging of 5HT1A receptors

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Christine BREFEL-COURBON, MD PhD · University Hospital, Toulouse

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2026-09-01
Completion
2026-09-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06008704 on ClinicalTrials.gov